TrialRheumatology (Oxford, England)2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Mark C Genovese et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this paperpooled ittrialcites it